Consolidated Balance Sheet Detail

6 Months Ended

Sep. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Note 4. Consolidated Balance Sheet Detail

Inventory

The following table summarizes inventory by category for the dates presented:


	September 30, 2022		March 31, 2022
Raw materials	$	5,215	$	10,228
Work in progress		2,398		7,154
Finished goods		5,145		4,654
Total inventories	$	12,758	$	22,036

Inventory at September 30, 2022 included $2,450 of raw materials, $0 of work in progress and $2,954 of finished goods related to the MosaiQ project. Inventory at March 31, 2022, included $6,761 of raw materials, $4,252 of work in progress and $2,758 of finished goods related to the MosaiQ project. During the quarter ended September 30, 2022, the Company recorded a write-off of $8.8 million in inventory and a $5.1 million write-off of prepaid assets related to the transfusion related MosaiQ assets. Included in other accrued expenses at September 30, 2022, is $1,228 of projected losses on firm purchase commitments recorded in other accrued expenses and $668 recorded in other long term liabilities related to the determination that certain firm purchase commitments no longer have an alternative future use.

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consist of the following:


	September 30, 2022		March 31, 2022
Accrued legal and professional fees	$	1,912	$	1,254
Accrued interest		5,247		9,235
Goods received not invoiced		2,780		1,304
Accrued capital expenditure		352		193
Other accrued expenses		4,754		3,743
Total accrued expenses and other current liabilities	$	15,045	$	15,729